Glycoprotein G : Unlocking the Broad-Spectrum Nipah Virus Vaccines

A recent study titled “An attachment glycoprotein nanoparticle elicits broadly neutralizing antibodies and protects against lethal Nipah virus infection,” published in npj Vaccines, describes a novel, safe, and effective self-assembled vaccine using a nanoparticle platform. This vaccine targets the head domain of the Nipah virus glycoprotein G, inducing broadly neutralizing antibodies that inhibit a range of Henipavirus infections and provide complete protection against Nipah virus in hamster models.

Explore ACROBiosystems' Nipah virus Glycoprotein G to enhance the efficacy evaluation of your Nipah virus vaccines!

Precise Detection: Tools for Evaluating the Potency of NiV Vaccines

Antigen quantification and immunogenicity assessment are critical performance indicators for ensuring the quality and efficacy of Nipah virus (NiV) vaccines. Click on the protocol to learn how to utilize Glycoprotein G for quantification antigen and evaluating vaccine efficacy against NiV.

Nipah & Hendra Virus: New era of vaccine development

Nipah virus (NiV) and Hendra virus (HeV) are both members of the Henipavirus genus within the Paramyxoviridae family, sharing highly similar virological characteristics. In recent research, scientists have focused on the head domain of the NiV glycoprotein (G) as a target antigen and successfully developed a novel, safe, and effective self-assembling protein nanoparticle vaccine. This advancement not only represents significant progress in Nipah virus vaccine development but also opens new possibilities for the development of vaccines targeting Hendra virus. Explore the NiV & HeV product list to learn more about these innovative developments and usher in a new era of vaccine innovation